The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2017:
- 30 negotiations are currently underway with 3 new files added since the last update of February 28, 2017:
- Votrient (pazopanib hydrochloride): Used to treat genitourinary metastatic renal cell carcinoma
- Campral (acamprosate calcium): Used to treat maintenance of alcohol abstinence
- Afinitor (everolimus): Used to treat neuroendocrine tumours of gastrointestinal or lung origin
- 148 joint negotiations have been completed with 5 files successfully negotiated and 1 file closed since the last update of February 28, 2017:
- Eylea (aflibercept): Used to treat macular edema secondary to branch retinal vein occlusion
- Enstresto (sacubitril/valsartan): Used to treat Heart Failure
- Entyvio (vedolizumab): Crohn’s disease
- Entyvio (vedolizumab): Used to treat ulcerative colitis
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide): Used to treat HIV-1 Infection
- Closed Negotiations
- Fentora (fentanyl buccal): Used to treat breakthrough cancer pain
- 50 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of February 28, 2017.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of February 28, 2017.
For more information, please consult the pCPA’s website.